Influence of glucose on the deoxyglucose metabolism in S cerevisiae: detection and identification of deoxyglucose and trehalose derivatives by 1H- and 13C-NMR spectroscopy.

J. Wietzerbin,M. Herve,S. Un,J. Neumann,A. Namane,S. Tran‐dinh

DOI: https://doi.org/10.1016/0300-9084(93)90134-E

IF: 4.372

Biochimie

Abstract:

What problem does this paper attempt to address?

[Use of healthcare services by elderly people in a local health authority in Varese (Italy)].

S. Pisani,O. Leoni,Luca Manfredi,D. Bonarrigo,M. Gambino,C. Oria,Beatrice Prandini,Renato Soma,F. Banfi

Abstract:Older people use more healthcare than younger people and aging of the population is considered to be one of the main factors leading to consumption of healthcare resources. The aim of this study was to evaluate rates of hospitalization, use of out-patient services and medicine confections among the elderly population (>65 years) in the local health authority of Varese (Italy), in the three-year period from 2003-2005, and to calculate the trend for the years 2006 and 2007. Rates of hospitalization and drug use remained stable while use of out-patient services showed an increasing trend. In spite of the influence of aging on consumption of healthcare resources, the use of medical services is determined mainly by the health state of the population: monitoring of the burden of morbidity in the population should therefore be improved.
Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study

Jia Xu,Hong Zhang,Hong Chen,Xiaoxue Zhu,Haiyan Jia,Zhongnan Xu,Dandan Huo,Cuiyun Li,Yanhua Ding

DOI: https://doi.org/10.1080/07853890.2023.2264850

Abstract:Background: TQA3526 is a novel farnesoid X receptor agonist developed to treat non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC). This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TQA3526 in healthy Chinese patients.Methods: Healthy subjects aged 18-55 years were enrolled in this double-blinded, first-in-human, placebo-controlled single ascending dose (1, 2, 5, and 10 mg) comprising food effect investigation (10 mg) and multiple dose study (2 mg and 0.2 + 0.5 + 1 mg). Safety was assessed on the basis of adverse events. The TQA3526 concentrations were analysed in the PK study. Alkaline phosphatase (ALP), fibroblast growth factor-19 (FGF19), bile acid precursor C4 (7α-hydroxy-cholest-4-ene-3-one), cholesterol, and bile acid were selected for PD analysis.Results: TQA3526 was well tolerated, and the primary adverse drug reaction was pruritus, as expected. The exposure to TQA3526 increased in a dose-dependent manner after a single dose of 1-10 mg. The exposure was higher after food intake. A steady state was reached around 5 days, and obvious plasma accumulation of TQA3526 was observed in the multiple dose study. TQA3526 increased circulating FGF-19 and decreased C4 levels in a dose-dependent manner. ALP increased only mildly in the 2 mg multiple dose cohort.Conclusions: TQA3526 (<10 mg/day) was safe and tolerable in healthy Chinese subjects. The safety profile and PK/PD characteristics of TQA3526 support further evaluation of patients with NASH or PBC. This study was registered at https://www.chictr.org.cn/ under the identifier ChiCTR1800019570.
Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial

Paul M O'Byrne,Hristo Metev,Margareta Puu,Kai Richter,Christina Keen,Mohib Uddin,Bengt Larsson,Marie Cullberg,Parameswaran Nair

DOI: https://doi.org/10.1016/S2213-2600(16)30227-2

Abstract:Background: Airway neutrophilic inflammation is a pathological feature in some patients with severe asthma. Stimulation of the chemokine receptor CXCR2 mediates neutrophil migration into the airways. We investigated the safety and efficacy of AZD5069, a CXCR2 antagonist, as an add-on therapy in patients with uncontrolled severe asthma. Methods: In this multicentre, randomised, double-blind, placebo-controlled, dose-finding trial, we enrolled patients aged 18 years or older with uncontrolled asthma despite combination therapy with long-acting β2 agonists and medium-dose or high-dose inhaled corticosteroids. Patients were randomised in a 1:1:1:1 ratio via an interactive voice-response or web-response system to receive 5, 15, or 45 mg oral AZD5069 twice daily or matched placebo. The primary endpoint was the number of severe asthma exacerbations in 6 months. Safety was assessed in the 6-month treatment period and an optional 6-month safety extension. This trial is registered with ClinicalTrials.gov, number NCT01704495. Findings: 640 patients with a mean age of 52 (SD 11·8) years were randomised, 478 to receive AZD5069 (5 mg n=160, 15 mg n=156, and 45 mg n=162) and 162 placebo. No dose of AZD5069 reduced the rate of severe exacerbations compared with placebo (rate ratio for 5 mg 1·29, 90% CI 0·79-2·11; for 15 mg 1·53, 0·95-2·46; and for 45 mg 1·56, 0·98-2·49). Treatment with AZD5069 was generally well tolerated. The most commonly reported adverse event overall was nasopharyngitis, seen in 18 (11·5%) receiving 5 mg, 13 (8·5%) receiving 15 mg, and 18 (11·2%) receiving 45 mg AZD5069, and 31 (19·5%) of those receiving placebo. Interpretation: Treatment with this selective CXCR2 antagonist did not reduce the frequency of severe exacerbations in patients with uncontrolled severe asthma. These findings bring into question the role of CXCR2-mediated neutrophil recruitment in the pathobiology of exacerbations in severe refractory asthma. Funding: AstraZeneca.
[Effectiveness of a lactobacillus vaccine on trichomonas infections in women. Preliminary results].

M. Litschgi,D. da Rugna,D. Mladenovic,R. Grčić

1980-11-06

Abstract:This is the report on a multi-centre study of the treatment of 444 women with trichomoniasis vaginalis using Solcotrichovac, a vaccine containing at least 7 x 10(9) inactivated microorganisms of various strains of lactobacillus acidophilus in each 0.5 ml dose. One year after the first vaccination 427 of the patients (96.2%) were followed up, and 92.5% of them were found to be cured of clinical symptoms; the remaining 7.5% must be considered as not cured, as either the slide or the culture was positive. We are convinced by these results that vaccination with Solcotrichovac represents an enhancement of therapeutic opportunities for the treatment of trichomoniasis vaginalis.
Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study

Bradley E Chipps,Frank C Albers,Laurence Reilly,Eva Johnsson,Christy Cappelletti,Alberto Papi

DOI: https://doi.org/10.1136/bmjresp-2021-001077

Abstract:Introduction: Uncontrolled asthma is associated with substantial morbidity. While fast-acting bronchodilators provide quick relief from asthma symptoms, their use as rescue fails to address the underlying inflammation. Combining a short-acting beta2-agonist, such as albuterol (salbutamol), with an inhaled corticosteroid, such as budesonide, in a single inhaler as rescue therapy could help control both bronchoconstriction and inflammation, and reduce the risk of asthma exacerbations. Methods and analysis: The Phase 3 MANDALA study was designed to determine the efficacy of albuterol in combination with budesonide (albuterol/budesonide 180/160 µg or 180/80 µg, two actuations of 90/80 µg or 90/40 µg, respectively) versus albuterol (180 µg, two actuations of 90 µg) as rescue therapy in adult, adolescent and paediatric patients with moderate-to-severe asthma. This event-driven study enrolled symptomatic patients (3000 adults/adolescents and 100 children aged 4-11 years) who experienced ≥1 severe asthma exacerbation in the previous year and were receiving maintenance therapy for ≥3 months prior to study entry. The primary efficacy endpoint was time-to-first severe asthma exacerbation. Ethics and dissemination: The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and Good Clinical Practice and the applicable regulatory requirements. Trial registration: NCT03769090.
Influence of Blood Flow and Vasoactive Drugs Upon Tissue Temperature Distributions In Local Hyperthermia Therapy

C. Babbs

Abstract:Effective local hyperthermia for cancer requires selective elevation of intratumoral temperature without overheating of surrounding normal tissues. Temperature elevation depends upon the balance between absorbed power density, which heats the treated tissue, and blood perfusion, which cools it. Selectivity can be achieved by manipulations of vascular physiology to increase blood cooling of normal tissues or to decrease blood cooling of tumor tissue. Creation of a favorable normal-to-tumor blood flow ratio is possible because the small blood vessels supplying most tumors are structurally and functionally different from the microvasculature of normal tissues. Normal arterioles dilate in heated tissues to raise local blood flow; whereas tumor vessels generally do not. This difference in vascular responsiveness provides a target for selective drug action that can be exploited to enhance local heat therapy of tumors. Vasodilator drugs, in particular, have profound effects upon the distribution of blood flow between tumor and adjacent normal tissues. Dilation of normal arterioles improves blood flow in normal tissues and may also shunt blood away from the tumors. These effects have been demonstrated in small animals, in large animals, and in humans to varying degrees. Further clinical exploitation of the microvascular differences between tumors and adjacent normal tissues may lead to improved effectiveness of hyperthermia therapy for a variety of tumor types. Supported by Grant CA-38144 from the National Cancer Institute, U.S. Public Health Service, Bethesda, Maryland. C. F. Babbs 2 Blood flow and temperature
Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial

Laurie A Lee,Zelie Bailes,Neil Barnes,Louis-Philippe Boulet,Dawn Edwards,Andrew Fowler,Nicola A Hanania,Huib A M Kerstjens,Edward Kerwin,Robert Nathan,John Oppenheimer,Alberto Papi,Steven Pascoe,Guy Brusselle,Guy Peachey,Neal Sule,Maggie Tabberer,Ian D Pavord

DOI: https://doi.org/10.1016/S2213-2600(20)30389-1

Abstract:Background: Despite inhaled corticosteroid plus long-acting β2-agonist (ICS/LABA) therapy, 30-50% of patients with moderate or severe asthma remain inadequately controlled. We investigated the safety and efficacy of single-inhaler fluticasone furoate plus umeclidinium plus vilanterol (FF/UMEC/VI) compared with FF/VI. Methods: In this double-blind, randomised, parallel-group, phase 3A study (Clinical Study in Asthma Patients Receiving Triple Therapy in a Single Inhaler [CAPTAIN]), participants were recruited from 416 hospitals and primary care centres across 15 countries. Participants were eligible if they were aged 18 years or older, with inadequately controlled asthma (Asthma Control Questionnaire [ACQ]-6 score of ≥1·5) despite ICS/LABA, a documented health-care contact or a documented temporary change in asthma therapy for treatment of acute asthma symptoms in the year before screening, pre-bronchodilator FEV1 between 30% and less than 85% of predicted normal value, and reversibility (defined as an increase in FEV1 of ≥12% and ≥200 mL in the 20-60 min after four inhalations of albuterol or salbutamol) at screening. Participants were randomly assigned (1:1:1:1:1:1), via central based randomisation stratified by pre-study ICS dose at study entry, to once-daily FF/VI (100/25 μg or 200/25 μg) or FF/UMEC/VI (100/31·25/25 μg, 100/62·5/25 μg, 200/31·25/25 μg, or 200/62·5/25 μg) administered via Ellipta dry powder inhaler (Glaxo Operations UK, Hertfordshire, UK). Patients, investigators, and the funder were masked to treatment allocation. Endpoints assessed in the intention-to-treat population were change from baseline in clinic trough FEV1 at week 24 (primary) and annualised moderate and/or severe asthma exacerbation rate (key secondary). Other secondary endpoints were change from baseline in clinic FEV1 at 3 h post-dose, St George's Respiratory Questionnaire (SGRQ) total score, and ACQ-7 total score, all at week 24. Change from baseline in Evaluating Respiratory Symptoms in Asthma total score at weeks 21-24 was also a secondary endpoint but is not reported here. Exploratory analyses of biomarkers of type 2 airway inflammation on treatment response were also done. This study is registered with ClinicalTrials.gov, NCT02924688, and is now complete. Findings: Between Dec 16, 2016, and Aug 31, 2018, 5185 patients were screened and 2439 were recruited and randomly assigned to FF/VI (100/25 μg n=407; 200/25 μg n=406) or FF/UMEC/VI (100/31·25/25 μg n=405; 100/62·5/25 μg n=406; 200/31·25/25 μg n=404; 200/62·5/25 μg n=408), with three patients randomly assigned in error and not included in analyses. In the intention-to-treat population, 922 (38%) patients were men, the mean age was 53·2 years (SD 13·1) and body-mass index was 29·4 (6·6). Baseline demographics were generally similar across all treatment groups. The least squares mean improvement in FEV1 change from baseline for FF/UMEC/VI 100/62·5/25 μg versus FF/VI 100/25 μg was 110 mL (95% CI 66-153; p<0·0001) and for 200/62·5/25 μg versus 200/25 μg was 92 mL (49-135; p<0·0001). Adding UMEC 31·25 μg to FF/VI produced similar improvements (FF/UMEC/VI 100/31·25/25 μg vs FF/VI 100/25 μg: 96 mL [52-139; p<0·0001]; and 200/31·25/25 μg vs 200/25 μg: 82 mL [39-125; p=0·0002]). These results were supported by the analysis of clinic FEV1 at 3 h post-dose. Non-significant reductions in moderate and/or severe exacerbation rates were observed for FF/UMEC 62·5 μg/VI versus FF/VI (pooled analysis), with rates lower in FF 200 μg-containing versus FF 100 μg-containing treatment groups. All pooled treatment groups demonstrated mean improvements (decreases) in SGRQ total score at week 24 compared with baseline in excess of the minimal clinically important difference of 4 points; however, there were no differences between treatment groups. For mean change from baseline to week 24 in asthma control questionnaire-7 score, improvements (decreases) exceeding the minimal clinically important difference of 0·5 points were observed in all pooled treatment groups. Adding UMEC to FF/VI resulted in small, dose-related improvements compared with FF/VI (pooled analysis: FF/UMEC 31·25 μg/VI versus FF/VI, -0·06 (95% CI -0·12 to 0·01; p=0·094) FF/UMEC 62·5 μg/VI versus FF/VI, -0·09 (-0·16 to -0·02, p=0·0084). By contrast with adding UMEC, the effects of higher dose FF on clinic trough FEV1 and annualised moderate and/or severe exacerbation rate were increased in patients with higher baseline blood eosinophil count and exhaled nitric oxide. Occurrence of adverse events was similar across treatment groups (patients with at least one event ranged from 210 [52%] to 258 [63%]), with the most commonly reported adverse events being nasopharyngitis (51 [13%]-63 [15%]), headache (19 [5%]-36 [9%]), and upper respiratory tract infection (13 [3%]-24 [6%]). The incidence of serious adverse events was similar across all groups (range 18 [4%]-25 [6%)). Three deaths occurred, of which one was considered to be related to study drug (pulmonary embolism in a patient in the FF/UMEC/VI 100/31·25/25 μg group). Interpretation: In patients with uncontrolled moderate or severe asthma on ICS/LABA, adding UMEC improved lung function but did not lead to a significant reduction in moderate and/or severe exacerbations. For such patients, single-inhaler FF/UMEC/VI is an effective treatment option with a favourable risk-benefit profile. Higher dose FF primarily reduced the rate of exacerbations, particularly in patients with raised biomarkers of type 2 airway inflammation. Further confirmatory studies into the differentiating effect of type 2 inflammatory biomarkers on treatment outcomes in asthma are required to build on these exploratory findings and further guide clinical practice. Funding: GSK.
Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis

Ludger Klimek,Jean Bousquet,David Price

DOI: https://doi.org/10.1517/14740338.2016.1122755

2015-12-23

Expert Opinion on Drug Safety

Abstract:INTRODUCTION: As a chronic disease, allergic rhinitis (AR) requires regular use of allergy medications for the effective management of symptoms. It is therefore imperative that AR treatments not only provide adequate symptom control but are also well tolerated.AREAS COVERED: MP29-02 (Dymista, Meda, Solna, Sweden) is the first new class of AR medication (WHO ATC R01AD58) since the introduction of intranasal corticosteroids (INS) almost 50 years ago. It is a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate delivered in a single spray. Here we review all the safety information relevant to MP29-02, from the initial phase I bioavailability and disposition data, to the phase III 14-day and 52-week data and finally to phase IV safety data collected during MP29-02 use in routine clinical practice.EXPERT OPINION: MP29-02 is the first real therapeutic advance in AR since the introduction of INS and has the potential to change the way this disease is managed, simplifying AR treatment regimens to a single puff in each nostril twice a day. Patients will benefit from superior symptom relief MP29-02 compared to INS with the added assurance that the safety of MP29-02 has been confirmed in the short term and long term as well as in real life.

pharmacology & pharmacy
[Molecular weight determination of lipopolysaccharides from rough-type gram-negative bacteria by SDS-polyacrylamide gel electrophoresis].

K. Amano,S. Mizushiri,K. Fukushi

DOI: https://doi.org/10.3412/JSB.43.911

1988-09-01

Abstract:サルモネラや大腸菌のR変異型LPSはSDS-ポリアクリルアミドゲル電気泳動(PAGE)によつて分子量に応じて泳動する。その泳動距離と分子量の間には直線関係が成立し,この方法を用いることによつて,R変異型LPSの分子量推定が可能となることが知られている。最適ゲル濃度は17.5%から20%の間であつた。R型LPSを持つといわれているクラミジア属(Chlamydia trachomatisとC. psittaci)のLPSを泳動したところ,約3,700の分子量を持つ単一のLPSであることが示された。一方,百日咳菌のLPSは株によつて少なくとも約4,500の分子量を持つ単一のLPSと,分子量約3,400の分子をも合わせ持つ複合LPSの2タイプあることがわかつた。以上の結果より,SDS-PAGEがクラミジアや百日咳菌のようなLPSの分子量推定に応用可能と考えられる。
Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First-in-Human, Randomized, Single-Blind, Placebo-Controlled Study

Kathleen Connolly,Richard George,Sami Omar,Elin Matsson,Magnus Åstrand,Magnus Althage,Daniel Pettersen,Esha Mohamed,Kelly Fang,Joao A C Lima,Mirjana Kujacic,Helena Ödesjö,Michelle Turton,Petra Johannesson,Anders Gabrielsen,Marcin Ufnal

DOI: https://doi.org/10.1161/JAHA.123.034067

2024-08-06

Abstract:Background: Heart failure mortality remains high despite recent progress in pharmacological treatment. AZD3427 is a selective long-acting analog of relaxin, a vasodilatory hormone with antifibrotic effects. We assessed the safety, pharmacokinetics, and pharmacodynamics of AZD3427 in healthy volunteers and patients with heart failure on standard-of-care therapy. Methods and results: In this first-in-human, phase 1a/b, randomized, single-blind, placebo-controlled study, healthy volunteers were randomized 6:2 to receive a single dose of AZD3427 or placebo by subcutaneous injection in 5 mixed-ethnicity cohorts (5, 10, 30, 90, or 270 mg) and 1 Japanese-descent cohort (270 mg), or by intravenous injection in 1 cohort (15 mg). After confirming safety and tolerability in healthy volunteers, 3 cohorts of patients with heart failure and left ventricular ejection fraction ≤40% and 3 cohorts with ejection fraction ≥41% were randomized 6:2 to receive 5 weekly doses of AZD3427 (5, 15, or 45 mg) or placebo by subcutaneous injection. In total, 56 healthy volunteers and 48 patients with heart failure were randomized. AZD3427 was well tolerated at all doses. After subcutaneous administration, AZD3427 was absorbed slowly, and exposure was approximately linear across the dose range. In patients with heart failure, AZD3427 terminal half-life was 13 to 14 days and there were numerical increases in stroke volume and estimated glomerular filtration rate. No treatment-emergent antidrug antibodies were detected. Conclusions: AZD3427 had favorable safety and pharmacokinetic profiles. Hemodynamic changes in patients with heart failure were consistent with the anticipated effects of a relaxin analog. These findings support further development of AZD3427 as a novel long-term treatment for patients with heart failure. Registration: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT04630067.
Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials

Sanjay Sethi,James F. Donohue,Gary T. Ferguson,Chris N. Barnes,Glenn D. Crater

DOI: https://doi.org/10.1177/1753466620905278

2020-01-01

Therapeutic Advances in Respiratory Disease

Abstract:Background: Combinations of a long-acting muscarinic receptor antagonist (LAMA), long-acting β-agonist (LABA), and inhaled corticosteroid (ICS) are used for patients with persistent chronic obstructive pulmonary disease (COPD) exacerbations on bronchodilator monotherapy. In this prespecified subgroup analysis, we assessed the efficacy and safety of the LAMA revefenacin in patients with COPD taking concomitant LABA, including ICS/LABA (LABA subgroup). Methods: Efficacy data were obtained from two 12-week, replicate, placebo-controlled trials and safety data were pooled from the 12-week and a 52-week tiotropium-controlled trial. Patients received revefenacin 175 μg or placebo in the 12-week or tiotropium 18 μg in the 52-week studies. The efficacy endpoint was least squares (LS) mean change from baseline in trough forced expiratory volume in 1 second (FEV 1 ). Clinical health outcomes were assessed using the St. George’s Respiratory Questionnaire (SGRQ). Results: Revefenacin produced similar improvements from baseline in trough FEV 1 in the non-LABA and LABA subgroups [placebo-adjusted LS mean change (95% confidence interval) in day 85 trough FEV 1 , 150.9 (110.3−191.6) ml and 139.2 (82.9−195.5) ml; p < 0.0001 versus placebo]. Similar improvements were observed in SGRQ scores in the non-LABA and LABA subgroups [−3.3 (−5.4 to −1.2) and −3.4 (−6.3 to −0.6)]. Improvements in lung function and health outcomes were observed regardless of airflow obstruction severity. Revefenacin was well tolerated with more adverse events reported in the LABA than the non-LABA subgroup. Conclusions: Once daily revefenacin for nebulization can be an effective and well-tolerated treatment for patients who require concomitant use of LABA with or without ICS. ClinicalTrials.gov identifiers: NCT02512510, NCT02459080, NCT02518139 The reviews of this paper are available via the supplemental material section.

respiratory system
Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma: Results of the DENALI Double-Blind Randomized Controlled Trial

Bradley E Chipps,Elliot Israel,Richard Beasley,Reynold A Panettieri Jr,Frank C Albers,Robert Rees,Lynn Dunsire,Anna Danilewicz,Eva Johnsson,Christy Cappelletti,Alberto Papi

DOI: https://doi.org/10.1016/j.chest.2023.03.035

IF: 9.6

Chest

Abstract:Background: In the phase 3 MANDALA trial, as-needed albuterol-budesonide pressurized metered-dose inhaler significantly reduced severe exacerbation risk vs as-needed albuterol in patients with moderate-to-severe asthma receiving inhaled corticosteroid-containing maintenance therapy. This study (DENALI) was conducted to address the US Food and Drug Administration combination rule, which requires a combination product to demonstrate that each component contributes to its efficacy. Research question: Do both albuterol and budesonide contribute to the efficacy of the albuterol-budesonide combination pressurized metered-dose inhaler in patients with asthma? Study design and methods: This phase 3 double-blind trial randomized patients aged ≥ 12 years with mild-to-moderate asthma 1:1:1:1:1 to four-times-daily albuterol-budesonide 180/160 μg or 180/80 μg, albuterol 180 μg, budesonide 160 μg, or placebo for 12 weeks. Dual-primary efficacy end points included change from baseline in FEV1 area under the curve from 0 to 6 h (FEV1 AUC0-6h) over 12 weeks (assessing albuterol effect) and trough FEV1 at week 12 (assessing budesonide effect). Results: Of 1,001 patients randomized, 989 were ≥ 12 years old and evaluable for efficacy. Change from baseline in FEV1 AUC0-6h over 12 weeks was greater with albuterol-budesonide 180/160 μg vs budesonide 160 μg (least-squares mean [LSM] difference, 80.7 [95% CI, 28.4-132.9] mL; P = .003). Change in trough FEV1 at week 12 was greater with albuterol-budesonide 180/160 and 180/80 μg vs albuterol 180 μg (LSM difference, 132.8 [95% CI, 63.6-201.9] mL and 120.8 [95% CI, 51.5-190.1] mL, respectively; both P < .001). Day 1 time to onset and duration of bronchodilation with albuterol-budesonide were similar to those with albuterol. The albuterol-budesonide adverse event profile was similar to that of the monocomponents. Interpretation: Both monocomponents contributed to albuterol-budesonide lung function efficacy. Albuterol-budesonide was well tolerated, even at regular, relatively high daily doses for 12 weeks, with no new safety findings, supporting its use as a novel rescue therapy. Clinical trial registration: ClinicalTrials.gov; No.: NCT03847896; URL: www. Clinicaltrials: gov.
Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability

Hans Ericsson,Karin Nelander,Maria Heijer,Magnus Kjaer,Eva-Lotte Lindstedt,Muna Albayaty,Pablo Forte,Maria Lagerström-Fermér,Stanko Skrtic

DOI: https://doi.org/10.1002/cpdd.756

Abstract:AZD5718 is a first-in-class small-molecule anti-inflammatory drug with the potential to reduce the residual risk of cardiovascular events after myocardial infarction in patients receiving lipid-lowering statin therapy. Leukotrienes are potent proinflammatory and vasoactive mediators synthesized in leukocytes via 5-lipoxygenase and 5-lipoxygenase-activating protein (FLAP). AZD5718 is a FLAP inhibitor that dose-dependently reduced leukotriene biosynthesis in a first-in-human study. We enrolled 12 healthy men in a randomized, open-label, crossover, single-dose phase 1 pharmacokinetic study of AZD5718 to investigate a potential drug-drug interaction with rosuvastatin, and the effects of formulation and food intake (ClinicalTrials.gov identifier: NCT02963116). Rosuvastatin (10 mg) were absorbed more rapidly when coadministered with AZD5718 (200 mg), probably owing to weak inhibition of hepatic statin uptake, but relative bioavailability was unaffected (geometric least-squares mean ratio [GMR], 100%; 90% confidence interval [CI], 86%-116%). AZD5718 pharmacokinetics were unaffected by coadministration of rosuvastatin. AZD5718 (200 mg) was absorbed less rapidly when formulated as tablets than oral suspension, with reduced relative bioavailability (GMR, 72%; 90%CI, 64%-80%). AZD5718 absorption was slower when 200-mg tablets were taken after a high-fat breakfast than after fasting, but relative bioavailability was unaffected (GMR, 96%; 90%CI, 87%-106%). In post hoc pharmacodynamic simulations, plasma leukotriene B4 levels were inhibited by >90% throughout the day following once-daily AZD5718, regardless of formulation or administration with food. AZD5718 was well tolerated, with no severe or serious adverse events. These data supported the design of a phase 2a efficacy study of AZD5718 in patients with coronary artery disease.
A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma

Dominic Brittain,Peter D'Andrea,Emilie Gruen,Motoi Hosoe,Devendra Jain,Juergen Jauernig,Abhijit Pethe,Emil Scosyrev,Ana-Maria Tanase,Hanns-Christian Tillmann

DOI: https://doi.org/10.1007/s12325-021-02025-w

Abstract:A novel, once-daily (o.d.), fixed-dose combination (FDC) of indacaterol acetate (IND), glycopyrronium bromide (GLY), and mometasone furoate (MF), delivered by the inhaler Breezhaler® device, is the first long-acting beta2-adrenergic agonist/long-acting muscarinic antagonist/inhaled corticosteroid (LABA/LAMA/ICS) therapy to be approved for maintenance treatment of asthma in adults inadequately controlled on LABA/ICS. The approval of IND/GLY/MF in the European Union (EU) also included an optional electronic sensor and smartphone (or other suitable device) application, making it the first "digital companion" that can be prescribed with an asthma medication. As a result, the European Medicines Agency included this approval as one of the "outstanding contributions to public health" (for Pneumology/Allergology) in their 2020 highlights report. Alongside IND/GLY/MF, an o.d. LABA/ICS FDC, IND/MF, was also developed and approved. This review outlines the unique strategy used in the accelerated development of IND/GLY/MF that combined various approaches: (1) selecting individual components with established efficacy/safety, (2) bridging doses to optimize efficacy/safety of IND/GLY/MF and IND/MF delivered via the Breezhaler® device, (3) developing IND/GLY/MF and IND/MF in parallel, and (4) submission for regulatory approval before formal completion of the pivotal phase III studies. IND/GLY/MF and IND/MF were combined in a single-development plan (PLATINUM program), which comprised four phase III studies: QUARTZ and PALLADIUM evaluated IND/MF while IRIDIUM and ARGON evaluated IND/GLY/MF. A unique feature was the inclusion of two LABA/ICS comparators in the pivotal IRIDIUM study-IND/MF as an internal comparator, and high-dose salmeterol xinafoate/fluticasone propionate (SAL/FLU) as a marketed comparator. In the ARGON study, IND/GLY/MF was compared against o.d. tiotropium (via Respimat®) plus twice-daily (b.i.d.) high-dose SAL/FLU (via Diskus®). As a result of this development strategy, the development and approval of IND/GLY/MF was accelerated by ca. 4 years as against what would be expected from a traditional approach, novel data were generated, and a unique optional digital companion was approved in the EU. A Video Abstract by Dr Dominic Brittain, Global Drug Development, Novartis. (MP4 228293 kb).
Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia

Kefang Lai,Dejun Sun,Ranran Dai,Ronnie Samoro,Hae-Sim Park,Annika Åstrand,David Cohen,Maria Jison,Vivian H Shih,Viktoria Werkström,Yuhui Yao,Yajuan Zhang,Wenying Zheng,Nanshan Zhong,MIRACLE Study Investigators,Principle investigators,Albay Albert Jr,Bo Jianping,Chen Bi,Chen Lijun,Chen Mei,Chen Min,Chen Ping,Chen Zhimin,Chian Chih-Feng,Cho You Sook,Fu Xiuhua,Gao Xiwen,Gu Wei,Han Wei,Han Zhihai,Hu Xi Wei,Huang Kewu,Huang Mao,Isidro Marie Grace Dawn,Jeong Inbeom,Jiang Luning,Jiang Mingyan,Jiang Shanping,Jin Meiling,Kang Jian,Kim Jin Woo,Kim Sang-Ha,Kuang Jiulong,Kuo Ping-Hung,Li Jie,Li Manxiang,Li Minjing,Li Ruoran,Li Wen,Li Xianhua,Li Yanming,Lim Seong Yong,Liu Chuanhe,Liu Chuntao,Liu Jing,Liu Xiaoxia,Lu Huiyu,Luo Zhuang,Ma Shengxi,Mao Liangping,Min Kyung Hoon,Mu Lin,Park Choon-Sik,Park Hae Sim,Park Hye-Kyung,Park Jung-Won,Perng Diahn-Warng,Samoro Ronnie,Shi Guochao,Sun Debin,Sun Dejun,Wang Chun-Hua,Wang Guangfa,Wang Limin,Wang Xuefen,Wang Yan,Wei Liping,Wu Haihong,Xiao Yi,Xiao Zuke,Xie Canmao,Xu Jin-Fu,Xu Xingxiang,Xu Xiyuan,Yan Jianping,Yang Hongzhong,Yoon Ho Joo,Yu Wencheng,Zhang Jin,Zhang Longju,Zhang Min,Zhang Wei,Zhao Jianping,Zhao Ziwen,Zhu Xiaoli,Zhu Yingqun,Other investigators,AstraZenenca,ClinChoice,Alipen Zara Ampordan,Capalla Marie Elaine,Cheng Ke-Bin,Jumeras Analyn,Kim Sae-Hoon,Kim Sei Won,Luis Jennifer San,Ma Jingfang,Sun Xiao-Li,Xiaolian Song,Yeo Chang Dong,Bu Wei,Han Bing,He Jiawen,Huang Xiaogian,Jia Lili,Li Hao,Li Xu,Ma Sammi,Martin Ubaldo,Miao Ida,Min Wendy,Odorisio Mark,Song Ailing,Tang Cailian,Wang Hongxia,Wang Yiran,White Mark,Wu Peibei,Wu Ray,Xia Tijiao,Xie Junhui,Yu Xinzheng,Zhou Zhengfang,Zhu Shuting,Lai Yutong,May Amanda,Shah Dipali,Shen Gang,Wang Conglong,Zhou Wenjiong

DOI: https://doi.org/10.1016/j.rmed.2024.107611

2024-04-01

Abstract:Background: Benralizumab is indicated as add-on therapy in patients with uncontrolled, severe eosinophilic asthma; it has not yet been evaluated in a large Asian population with asthma in a clinical trial. Objective: To evaluate the efficacy and safety of benralizumab in patients with severe asthma in Asia. Methods: MIRACLE (NCT03186209) was a randomized, Phase 3 study in China, South Korea, and the Philippines. Patients aged 12-75 years with severe asthma receiving medium-to-high-dose inhaled corticosteroid/long-acting β2-agonists, stratified (2:1) by baseline blood eosinophil count (bEOS) (≥300/μL; <300/μL), were randomized (1:1) to benralizumab 30 mg or placebo. Endpoints included annual asthma exacerbation rate (AAER; primary endpoint), change from baseline at Week 48 in pre-bronchodilator (BD) forced expiratory volume in 1 second (pre-BD FEV1) and total asthma symptom score (TASS). Safety was evaluated ≤ Week 56. Results: Of 695 patients randomized, 473 had baseline bEOS ≥300/μL (benralizumab n = 236; placebo n = 237). In this population, benralizumab significantly reduced AAER by 74% (rate ratio 0.26 [95% CI 0.19, 0.36], p < 0.0001) and significantly improved pre-BD FEV1 (least squares difference [LSD] 0.25 L [95% CI 0.17, 0.34], p < 0.0001) and TASS (LSD -0.25 [-0.45, -0.05], p = 0.0126) versus placebo. In patients with baseline bEOS <300/μL, there were numerical improvements in AAER, pre-BD FEV1, and TASS with benralizumab versus placebo. The frequency of adverse events was similar for benralizumab (76%) and placebo (80%) in the overall population. Conclusions: MIRACLE data reinforces the efficacy and safety of benralizumab for severe eosinophilic asthma in an Asian population, consistent with the global Phase 3 results.
[Effects of temperature and pH on digestive enzymes activities in Whitmania pigra].

Hongzhuan Shi,Q. Guo,Zaibiao Zhu,T. Hu,Shuai-wen Zhang

DOI: https://doi.org/10.4268/cjcmm20121707

2012-09-01

Abstract:OBJECTIVE Current study was conducted to investigate and compare the impact of temperature and pH on the activities of amylase, protease and lipase in alimentary tract of Whitmania pigra. METHOD The responses of amylase, protease, and lipase activities were determined over a wide range of temperatures (7-52 degrees C) and pH gradient (2.2-11.2). RESULT The highest lipase activity was found under 37 degrees C, pH 8.2, and the highest amylase activity was detected under 37 degrees C, pH 5.2, while protease activity peaked at 42 degrees C, pH 3.2 or pH 9.2. CONCLUSION The optimal temperature in alimentary tract of Wh. pigra for lipase and amylase was 37 degrees C, and the responding temperature for protease was 42 degrees C. The optimal pH value in alimentary tract of Wh. pigra for lipase and amylase was pH 8.2 and pH 5.2, respectively. While pH 3.2 or 9.2 seems to be both favorable for high protease activity.
Efficacy and Safety of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray in Treating Allergic Rhinitis: a Randomized Controlled Trial

Xinling Han,Chengshuo Wang,Qinna Zhang,Bing Guan,Hua Zhang,Yafeng Yu,Jinyong Tang,Xiaoping Gao,Juan Meng,Chao Li,Huifang Zhou,Xinsheng Huang,Haiyun Shi,Tao Bian,Guohua Hu,Qingshan Jiang,Huabin Li,Lingbo Li,Xianhua Li,Chang Lin,Dingrong Liu,Jixiang Liu,Huaan Ma,Guolin Tan,Lijia Wan,Jiao Xia,Shuifang Xiao,Jinghua Xie,Zhimin Xing,Shenhong Qu,Changqing Zhao,Li Zhu,Yuan Zhang,Luo Zhang

DOI: https://doi.org/10.5415/apallergy.0000000000000161

2024-01-01

Asia Pacific Allergy

Abstract:Background: MP-AzeFlu (Dymista; Meda Pharma GmbH & Co., KG), a formulation combining azelastine hydrochloride and fluticasone propionate in a single spray, is superior to fluticasone propionate alone in relieving symptoms and improving the quality of life of patients with allergic rhinitis. Objectives: In this study, we evaluated whether the effect of AzeFlu, a generic drug manufactured from China, is equivalent to that of MP-AzeFlu. Methods: In total, 679 patients were recruited for a multicentre, randomized, double-blind, original drug-controlled, and parallel-group clinical trial. Overall, 339 and 340 patients were administered with AzeFlu and MP-AzeFlu, respectively. Efficacy was assessed by changes in the reflective total nasal symptom score, the area under the curve of reflective total nasal symptom score changes over time, changes from baseline in individual nasal symptom scores, and the Rhinoconjunctivitis Quality of Life Questionnaire. In addition, a safety evaluation was simultaneously performed. Results: AzeFlu and MP-AzeFlu reduced the reflective total nasal symptom score from baseline (AzeFlu −6.7 [standard deviation, 2.59]; MP-AzeFlu −6.7 [standard deviation, 2.76]; P = 0.905) and improved nasal symptoms and quality of life (AzeFlu −62.3 [standard deviation, 33.59]; MP-AzeFlu −64.7 [standard deviation, 33.73]; P = 0.394) in patients with allergic rhinitis. Significant differences were not observed between groups. Conclusion: AzeFlu showed effects equivalent to those of MP-AzeFlu in this clinical trial and may benefit Chinese patients with allergic rhinitis. Registration number: CTR20190189 (chinadrugtrials.org.cn/index.html)
Studies on shock during extracorporeal circulation during aorto-coronary bypass operations.

W. Heller,G. Fuhrer,H. Hoffmeister,M. Gallimore

Abstract:
Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis

Ikuo Hirano,Ekaterina Safroneeva,Marie C. Roumet,Gail M. Comer,Gina Eagle,Alain Schoepfer,Gary W. Falk

DOI: https://doi.org/10.1111/apt.15670

2020-03-09

Abstract:BackgroundAPT‐1011, a fluticasone propionate orally disintegrating tablet formulation, is under investigation for the treatment of eosinophilic oesophagitis (EoE). AimsTo evaluate the safety and tolerability of APT‐1011 administered to patients with EoE and to assess the effect on clinical symptoms of EoE, endoscopic appearance and oesophageal eosinophilia. MethodsA randomised, double‐blind, placebo‐controlled, multicentre, phase 1b/2a study was conducted at seven medical centres in the US to evaluate the safety and tolerability of APT‐1011 over 8 weeks in adults and adolescents with EoE. Participants were randomised to placebo (n = 8), 1.5 mg APT‐1011 BID (n = 8) or 3.0 mg APT‐1011 QD (n = 8). Safety and tolerability were assessed as the primary outcome; histologic and endoscopic measures were assessed as exploratory outcomes. ResultsThere were no deaths, serious treatment‐emergent adverse events (TEAEs), severe TEAEs or discontinuations from the study related to a TEAE. In one participant randomised to 1.5 mg APT‐1011 BID, a reduction in cortisol was observed, but without evidence of adrenal insufficiency. Compared with placebo, treatment with APT‐1011 resulted in greater reductions in oesophageal eosinophil counts, EoE Endoscopic Reference Score, patient global assessment and symptom‐based EoE activity index from baseline to end of treatment (Week 8). ConclusionsAPT‐1011 was safe and well tolerated in adolescents and adults with EoE. Exploratory efficacy outcomes demonstrated improvement in histologic and endoscopic findings as well evidence of symptom improvement. The results of this study support the continued development of APT‐1011 for the treatment of EoE (NCT‐01386112).

pharmacology & pharmacy,gastroenterology & hepatology
(065) A Randomized, Single-Dose, Bioavailability and Safety Study on Novel SDS-089 Nasal Vardenafil 4mg Spray Solution in Comparison to Oral Vardenafil Tablet 10 mg in Healthy Volunteers

E Professor,D Zanardo,L Rodne,S White

DOI: https://doi.org/10.1093/jsxmed/qdae002.060

2024-03-06

The Journal of Sexual Medicine

Abstract:Introduction Oral phosphodiesterase type 5 inhibitor (PDE5i) is recognized as an effective first-line medical therapy for males with erectile dysfunction. However, oral PDE5i drug adherence and satisfaction rates were not high due to the need for oral ingestion, lack of sexual spontaneity, and delay in time to clinical effect. Hence, a nasal delivery of PDE5i drug may circumvent these limitations. Objective To assess the bioavailability and safety profile of SDS-089 nasal Vardenafil spray compared to oral Vardenafil 10mg tablet. Methods Following approval from Institutional Review Board and Biosafety Committee (FB18/IRB/099), 13 subjects out of the 32 healthy volunteers met the study criteria and were randomized to receive SDS-089 nasal Vardenafil spray (4 mg) or oral Vardenafil tablet (10 mg). The vardenafil HCl formulation SDS-089 was prepared with the active pharmaceutical ingredient meeting the United States Pharmacopeia (USP) standard (batch 1704002361). Blood tests were conducted on the subjects to evaluate Vardenafil drug bioavailability and treatment-related adverse events (TRAEs) data was collected. Results All 13 subjects completed the study. Based on the drug pharmacokinetics data, SDS-089 nasal spray was shown to have a faster onset and achieve optimal dose with a lower amount of drug compared to oral formulation. Of the 42 recorded TRAEs, 33 TRAEs were associated with the nasal spray, and 9 TRAEs were related to oral drugs. Transient headache is the most common TRAE in the nasal group and was very tolerable. The reported headaches showed no relationship with Cmax (peak concentration) and AUC0-inf (the total drug exposure across time) based on the Vardenafil drug levels. Conclusions SDS-089 nasal spray formulation Vardenafil HCl at 4 mg successfully achieved a similar Cmax with that of oral Vardenafil 10 mg tablet, and while it appeared to have more TRAEs, these were transient and well-tolerated by the subjects. Disclosure Yes, this is sponsored by industry/sponsor: LTR Pharma. Clarification: Industry funding only - investigator initiated and executed study.

urology & nephrology

Influence of glucose on the deoxyglucose metabolism in S cerevisiae: detection and identification of deoxyglucose and trehalose derivatives by 1H- and 13C-NMR spectroscopy.

[Use of healthcare services by elderly people in a local health authority in Varese (Italy)].

Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study

Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial

[Effectiveness of a lactobacillus vaccine on trichomonas infections in women. Preliminary results].

Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study

Influence of Blood Flow and Vasoactive Drugs Upon Tissue Temperature Distributions In Local Hyperthermia Therapy

Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial

Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis

[Molecular weight determination of lipopolysaccharides from rough-type gram-negative bacteria by SDS-polyacrylamide gel electrophoresis].

Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First-in-Human, Randomized, Single-Blind, Placebo-Controlled Study

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials

Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma: Results of the DENALI Double-Blind Randomized Controlled Trial

Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability

A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma

Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia

[Effects of temperature and pH on digestive enzymes activities in Whitmania pigra].

Efficacy and Safety of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray in Treating Allergic Rhinitis: a Randomized Controlled Trial

Studies on shock during extracorporeal circulation during aorto-coronary bypass operations.

Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis

(065) A Randomized, Single-Dose, Bioavailability and Safety Study on Novel SDS-089 Nasal Vardenafil 4mg Spray Solution in Comparison to Oral Vardenafil Tablet 10 mg in Healthy Volunteers